[Studies on the pharmacokinetics of Sulfaclomid, Mebacid, Nevigramon and Metindol in patients with reduced kidney function].
In patients with restriction of the renal function the pharmacokinetics of Sulfaclomid, Mebacid, Nevigramon and Metindol was investigated. According to the different elimination mechanisms of the drugs investigated the kinetics was infleunced in different way by the restriction of the renal elimination of these drugs: The half-life periods for the elimination of Metindol, Nevigramon and Mebacid remained unchanged in patients with renal diseases; the half-value period for the elimination of Sulfaclomid was prolonged.
D003401:Creatine / Q000378:metabolism; D006801:Humans; D007213:Indomethacin / Q000378:metabolism / Q000627:therapeutic use*; D007668:Kidney / Q000378:metabolism; D007674:Kidney Diseases / Q000188:drug therapy*; D009268:Nalidixic Acid / Q000378:metabolism / Q000627:therapeutic use*; D011743:Pyrimidines / Q000378:metabolism / Q000627:therapeutic use; D013416:Sulfamerazine / Q000378:metabolism / Q000627:therapeutic use*; D013424:Sulfanilamides / Q000378:metabolism / Q000627:therapeutic use*
D011743:Pyrimidines; D013424:Sulfanilamides; D009268:Nalidixic Acid; D003401:Creatine; D013416:Sulfamerazine; D007213:Indomethacin
Untersuchungen zur Pharmakokinetik von Sulfaklomid, Mebacid, Nevigramon und Metidol bei Patienten mit eingeschränkter Nierenfunktion.